NCT01266603 - High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 22, 2011

Primary Completion Date

November 1, 2018

Study Completion Date

November 1, 2018

Conditions

Melanoma

Interventions

DRUG

HDIL-2

720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle.

BIOLOGICAL

recMAGE-A3 + AS15

300 μg plus 420 μg of CpG7909 (a part of the Adjuvant System AS15) by intermuscular injection within 24 hours from first dose of HDIL-2.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston